Clinical Trials Browser

Neoplasms × Docetaxel × Clear all

NCT05954312 2026-03-18

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Neoplasms

NCT04928846 2026-03-16

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05382559 2026-03-02

A Study of ASP3082 in Adults With Advanced Solid Tumors

Phase 1 Recruiting

Neoplasm Metastasis, Neoplasms

NCT07366528 2026-01-26

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

Phase 3 Recruiting

Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT03595059 2025-12-10

A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

Phase 1 Completed

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Small Cell Lung Carcinoma

NCT05516914 2025-11-28

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Phase 1/2 Recruiting

Neoplasms

NCT00600496 2025-11-13

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT02817633 2025-10-28

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Phase 1 Active not recruiting

DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

NCT06228326 2025-10-24

KYANITE-1

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT06623656 2025-10-23

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Phase 2 Recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT03505320 2025-10-20

ILUSTRO

Phase 2 Active not recruiting

Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT06463665 2025-09-26

VIRO-25

Phase 2 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT05381038 2025-09-23

Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

Phase 1/2 Recruiting

BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms, Neoplasms

NCT06632951 2025-08-11

LIVIGNO-3

Phase 2 Active not recruiting

Carcinoma, Transitional Cell, Neoplasms

NCT04306900 2025-07-29

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Phase 1 Completed

185 enrolled 28 charts

GastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04721015 2025-07-03

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03739710 2025-06-15

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

175 enrolled 5 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06028737 2025-05-06

OCTASUR

Phase 2/3 Recruiting

Gastrointestinal

Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms

NCT00446225 2025-03-05

EURTAC

Phase 3 Completed

174 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03837977 2024-12-30

NET02

Phase 2 Completed

Neoplasms, Carcinoma, Neuroendocrine

NCT02723955 2024-12-27

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Phase 1 Completed

829 enrolled 100 charts

Neoplasms

NCT00798070 2024-12-18

PANTHER

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasms

NCT02009449 2024-11-15

IVY

Phase 1 Completed

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT01957436 2024-11-12

PEACE1

Phase 3 Active not recruiting

Neoplasms, Prostatic Neoplasms

NCT03693612 2024-08-28

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

Phase 1/2 Completed

26 enrolled 47 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms

NCT00587431 2023-11-07

Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer

Phase 2 Completed

102 enrolled 8 charts

Neoplasms, Prostatic Neoplasms

NCT05094804 2023-11-02

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Phase 1/2 Unknown

DermatologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Leiomyosarcoma, Liposarcoma, Melanoma, Neoplasm Metastasis, Neoplasms

NCT00020046 2023-10-31

Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer

Phase 2 Completed

Neoplasms, Prostatic Neoplasms, Genetic Diseases, Inborn

NCT02126969 2023-03-13

A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN

Phase 2 Completed

45 enrolled 13 charts

Head and Neck Neoplasms, Laryngeal Diseases, Neoplasms

NCT05553808 2023-01-19

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1

Phase 2 Completed

105 enrolled 31 charts

Neoplasms

NCT01920061 2022-09-13

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Phase 1 Completed

110 enrolled 80 charts

Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT01362374 2022-01-12

Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT02403531 2020-06-02

Induction Chemotherapy Followed by Chemoradiotherapy in Esophageal Cancer

Phase 2 Completed

Gastrointestinal

Esophageal Neoplasms, Neoplasms

NCT02117024 2020-02-05

A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Phase 2 Terminated

66 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03057366 2019-11-18

A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors

Phase 1 Completed

8 enrolled 26 charts

Neoplasms

NCT00848718 2019-11-12

MK-2206-003

Phase 1 Completed

77 enrolled 24 charts

Neoplasms

NCT01868022 2019-08-19

Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

Phase 1 Completed

65 enrolled 32 charts

Neoplasms

NCT02322281 2019-08-14

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Phase 3 Terminated

149 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Recurrence

NCT02900742 2019-04-12

Clinical Study of Chinese Medicine Plus Chemotherapy Maintenance in Advanced Non Small Cell Lung Cancer

Phase 3 Completed

Lung Neoplasms, Neoplasms

NCT00979641 2019-03-28

AINO

Phase 2 Terminated

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01376310 2019-02-19

GSK1120212 Rollover Study

Phase 2 Terminated

159 enrolled 9 charts

Neoplasms

NCT00089609 2018-04-20

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

Phase 2 Completed

73 enrolled 16 charts

Neoplasms, Prostatic Neoplasms

NCT00148902 2017-12-06

Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)

Phase 1 Completed

Breast Neoplasms, Neoplasms

NCT00201812 2017-12-06

Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT01472016 2017-11-21

Study of ABT-700 in Subjects With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT01192165 2017-11-13

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Phase 1 Completed

Neoplasms

NCT02474186 2017-08-03

Phase II Study for Solid Metastatic Tumors

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00226239 2017-07-11

Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer

Phase 2 Completed

39 enrolled 10 charts

Neoplasms

NCT00591149 2017-06-14

Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer

Phase 2 Terminated

16 enrolled 5 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms, Neoplasms, Squamous Cell